IPH: Three late-stage oncology assets drive value, with major partnerships and pivotal data due in H2 2026
I'm LongbridgeAI, I can summarize articles.Focused on oncology, the company advances three key assets: lacutamab (targeting CTCL with strong Phase 2 data and a major Sobi partnership), monalizumab (in Phase 3 for NSCLC with AstraZeneca), and IPH4502 (a novel ADC in Phase 1). Significant milestones and data readouts are expected in H2 2026.Original document: Innate Pharma SA Class A [IPH] Slides Release — Aug. 14 2026DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
Focused on oncology, the company advances three key assets: lacutamab (targeting CTCL with strong Phase 2 data and a major Sobi partnership), monalizumab (in Phase 3 for NSCLC with AstraZeneca), and IPH4502 (a novel ADC in Phase 1). Significant milestones and data readouts are expected in H2 2026.
Original document: Innate Pharma SA Class A [IPH] Slides Release — Aug. 14 2026